{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=9&state=Texas", "query": { "state": "Texas", "city": "Dallas", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 13764, "total_pages": 1377, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=10&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=8&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T02:07:22.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04128579", "title": "Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Erythematosus", "Lupus Nephritis" ], "interventions": [ { "name": "Itolizumab [Bmab 600]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biocon Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 52, "start_date": "2019-10-01", "completion_date": "2024-01-18", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 19, "location_summary": "Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04128579" }, { "nct_id": "NCT01722188", "title": "Lead Registry for Optim Leads", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Optim Lead Insulation Related Adverse Events" ], "interventions": [], "intervention_types": [], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14124, "start_date": "2006-08", "completion_date": "2020-07", "has_results": false, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 245, "location_summary": "Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Gadsden", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01722188" }, { "nct_id": "NCT03410056", "title": "Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rheumatoid Arthritis RA" ], "interventions": [ { "name": "Efavaleukin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2018-05-22", "completion_date": "2020-05-13", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 5, "location_summary": "Anniston, Alabama • Torrance, California • Lansing, Michigan + 2 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "Lansing", "state": "Michigan" }, { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03410056" }, { "nct_id": "NCT00467051", "title": "Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Extracranial Germ Cell Tumor", "Childhood Extragonadal Malignant Germ Cell Tumor", "Childhood Malignant Ovarian Germ Cell Tumor", "Childhood Malignant Testicular Germ Cell Tumor", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Yolk Sac Tumor", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Ovarian Germ Cell Tumor", "Testicular Choriocarcinoma", "Testicular Embryonal Carcinoma", "Testicular Mixed Choriocarcinoma and Embryonal Carcinoma", "Testicular Mixed Choriocarcinoma and Yolk Sac Tumor", "Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Yolk Sac Tumor" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 20, "start_date": "2007-11-05", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 85, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00467051" }, { "nct_id": "NCT01563029", "title": "A Dose-ranging Study of Fluticasone Furoate (FF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Furoate", "type": "DRUG" }, { "name": "Fluticasone Propionate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "5 Years to 11 Years" }, "enrollment_count": 597, "start_date": "2012-03-28", "completion_date": "2014-09-24", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 37, "location_summary": "Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01563029" }, { "nct_id": "NCT00864253", "title": "A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 529, "start_date": "2009-04-23", "completion_date": "2014-02-12", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00864253" }, { "nct_id": "NCT05602194", "title": "Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Acute Lymphoblastic Leukemia, BCR-ABL1-Like", "Lymphoblastic Lymphoma", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 440, "start_date": "2023-08-24", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 225, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602194" }, { "nct_id": "NCT06892522", "title": "A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "ABBV-2001", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2025-06-30", "completion_date": "2036-03", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 15, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06892522" }, { "nct_id": "NCT06675929", "title": "A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Compensated Liver Cirrhosis", "Metabolic Dysfunction Associated Steatohepatitis (MASH)" ], "interventions": [ { "name": "BI 770371", "type": "DRUG" }, { "name": "Placebo for BI 770371", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2025-01-20", "completion_date": "2026-01-13", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 13, "location_summary": "Chandler, Arizona • Coronado, California • Montclair, California + 8 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06675929" }, { "nct_id": "NCT02392351", "title": "Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Renal Denervation (Vessix)", "type": "DEVICE" }, { "name": "Renal Angiography", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 51, "start_date": "2015-04", "completion_date": "2019-08-02", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-11-03T02:07:22.215Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami Beach, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Houma", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392351" } ] }